drugset / Trial / NCT02301494

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

NCT02301494

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).

Timeline

Start
2020-04
Primary completion
2022-04
Completion
2023-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluocinonide Other / unclassified 0.1 % Topical
Subject Imiquimod Other / unclassified 3.75 % Topical

Indications